Trial
NCT04099836
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
Atezolizumab
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-26